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OBJECTIVES To determine the acute effects of type 5 phosphodiesterase inhibition with sildenafil on
flow-mediated vasodilation in the brachial artery of patients with chronic heart failure.
BACKGROUND Impaired endothelium-dependent, flow-mediated vasodilation in patients with heart failure is
partly attributable to hyporesponsiveness of cyclic guanosine monophosphate (cGMP)
mediated vasorelaxation effector mechanisms in vascular smooth muscle. The effect of
inhibition of cGMP degradation with sildenafil, a specific type 5 cGMP phosphodiesterase
inhibitor, on flow-mediated dilation in heart failure is unknown.
METHODS Flow-mediated vasodilation after release of 1, 3 and 5 min of transient arterial occlusion was
measured in the brachial artery with high resolution two-dimensional ultrasound imaging in
48 patients with chronic heart failure before and 1 h after randomized, double-blind
assignment to a single oral dose of sildenafil 12.5, 25 or 50 mg or matching placebo.
RESULTS In response to oral administration of a single dose of study drug, the change in flow-mediated
vasodilation after release of 1, 3 and 5 min of arterial occlusion was significantly greater in
patients receiving sildenafil 25 mg (3.3 6 1.9, 3.8 6 1.8 and 4.0 6 1.8%, respectively, p ,
0.05) and patients receiving sildenafil 50 mg (3.7 6 1.3, 4.1 6 1.1, 3.9 6 1.3%, respectively,
p , 0.05) than that of patients receiving placebo (0.7 6 1.1, 0.2 6 1.2, 0.6 6 0.8%,
respectively).
CONCLUSIONS Acute type 5 phosphodiesterase inhibition with sildenafil 25 and 50 mg increases
endothelium-dependent, flow-mediated vasodilation in patients with chronic heart failure
when compared with placebo. (J Am Coll Cardiol 2000;36:845–51) © 2000 by the American
College of Cardiology
The vascular endothelium plays an important role in the
normal regulation of peripheral vasomotor tone in conduit
and resistance blood vessels (1). Nitric oxide, released by
vascular endothelial cells in response to hormonal agonists
and shear stress, induces vasorelaxation by increasing pro-
duction of the second messenger cyclic guanosine mono-
phosphate (cGMP) via the activation of soluble guanylate
cyclase in vascular smooth muscle (2).
Agonist-induced and shear stress-induced nitric oxide-
mediated vasodilation are decreased in the skeletal muscle
circulation of patients with heart failure when compared
with age-matched normal subjects (3,4). Impaired nitric
oxide mediated vasodilation in heart failure is partly attrib-
utable to hyporesponsiveness of vasorelaxation effector
mechanisms in vascular smooth muscle (5–7). The vasodi-
latory responses to administration of endothelium-
independent cGMP-mediated vasodilatory agents such as
nitroglycerin, nitroprusside (soluble guanylate cyclase acti-
vators) and atrial and brain natriuretic peptides (particulate
guanylate cyclase activators) are decreased in patients with
congestive heart failure when compared with normal sub-
jects (6,8).
Vascular smooth muscle responses to cGMP-dependent
vasodilatory stimuli are regulated by the activity of vascular
smooth muscle phosphodiesterase, which catalyzes hydro-
lyzation of cGMP to inactive products (9). Seven isozymes
of phosphodiesterases have been identified in mammalian
tissues (10). Type 5 phosphodiesterase is the predominant
isozyme that contributes to regulation of cGMP content in
vascular smooth muscle (9,10). Sildenafil is a specific inhib-
itor of type 5 phosphodiesterase that has been approved for
the treatment of erectile dysfunction in humans (11–14).
The effect of type 5 phosphodiesterase inhibition with
sildenafil on endothelium-dependent vasodilation in pa-
tients with heart failure is unknown.
Accordingly, the present randomized, double-blind,
placebo-controlled study was undertaken to assess the acute
effects of type 5 phosphodiesterase inhibition with three
doses of sildenafil on flow-mediated endothelium-
dependent vasodilation in the forearm circulation of ambu-
latory patients with chronic congestive heart failure. The
study was designed to test the hypothesis that acute inhi-
bition of cGMP degradation with sildenafil will increase
flow-mediated vasodilation in the brachial artery when
compared with placebo.
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METHODS
Patient population. Thirty-nine men and nine women
with symptomatic congestive heart failure were studied.
Patients between the ages of 21 and 75 years with chronic
heart failure for .3 months duration, stable symptoms
compatible with New York Heart Association class II or III
and left ventricular ejection fraction ,40%, determined by
radionuclide angiography or echocardiography, were eligible
for the study. Criteria for exclusion were systolic blood
pressure ,90 mm Hg, heart rate ,50 beats per minute,
therapy with long-acting nitrate preparations, history of
intolerance of sildenafil and myocardial infarction, unstable
angina, stroke or open heart surgery within the preceding
12 months. Patients were receiving stable doses of diuretics
(n 5 48), angiotensin-converting enzyme inhibitors (n 5
48), digoxin (n 5 46) and beta-adrenergic receptor antag-
onists (n 5 28) for at least four weeks before the study. All
cardiac medications were discontinued at least 12 h before
the study.
Eight men and four women without a history of cardio-
vascular disease served as normal control subjects to provide
a comparison group for baseline pretreatment measurements
in heart failure patients. Normal subjects did not receive the
study drug. Normal subjects were nonsmokers with no
history of cardiovascular or other chronic disease. The mean
age of the normal subjects (49 6 5 years) did not differ from
that of the heart failure patients. The protocol was approved
by the ethical review committee at Columbia Presbyterian
Medical Center. All subjects gave written informed consent
before participation.
Brachial artery ultrasound imaging. Flow-mediated,
endothelium-dependent vasodilation in response to tran-
sient arterial occlusion was determined with ultrasono-
graphic imaging of the brachial artery with an 11 MHz
linear array ultrasound transducer connected to an ATL
Apogee 800 plus duplex ultrasound machine (Advanced
Technology Laboratories, Bothell, Washington) adapted
from previously published methods (15,16). The axial res-
olution of the 11 MHz transducer is capable of detection of
changes in brachial artery diameter of ,0.1 mm. Arterial
diameter (cm) was determined as the internal dimension of
the vessel wall, from trailing edge to leading edge of the
anterior and posterior intimal markings, respectively (to
confirm full alignment of the ultrasound beam with the
maximum anterior-posterior diameter of the brachial artery
in its long axis). Brachial artery blood flow velocity was
determined with a 1.2 mm pulsed Doppler ultrasound
sampling volume placed in the center of the image of the
vessel lumen with internal software correction for the
incident angle of 60°. Mean blood flow velocity (cm/s) was
determined by calculation of the area under the hand-traced
curve of the velocity spectral display. Brachial artery diam-
eter and blood flow velocity were measured at rest and after
release of transient arterial occlusion induced by inflation of
a forearm blood pressure cuff to suprasystolic pressure for 1,
3 and 5 min. Submaximal (1 and 3 min occlusions) and
maximal (5 min occlusion) vasodilatory stimuli were utilized
to determine whether a ceiling effect in response to a
maximal stimulus might mask drug effects apparent at
submaximal stimuli. Sequential occlusions were performed
at 5 to 15 min intervals, when blood flow velocity and
arterial diameter had returned to baseline. Blood flow
velocity was measured for 15 s immediately upon release of
the occluding cuff; the mean velocity of the first five beats
after release was averaged. Brachial artery diameter was
measured at end-diastole 60 to 75 s after release of the
occluding cuff; five diameter measurements were averaged.
Flow-mediated dilation was determined as the percent
change in brachial artery diameter after cuff release com-
pared with the resting brachial artery diameter.
Study design. This was a prospective, double-blind study
of three ascending doses of sildenafil versus placebo. The
study drug consisted of a single oral dose of sildenafil (12.5,
25 or 50 mg) or matching placebo prepared by the Colum-
bia Presbyterian Medical Center Research Pharmacy from
sildenafil citrate tablets (Viagra, Pfizer U.S. Pharmaceuti-
cals, New York, New York). Treatment assignment was
randomly allocated within three blocks of 16 patients (12
sildenafil, 4 placebo in each block) in ascending dose order.
Subjects were studied in the postabsorptive state. Brachial
artery diameter and blood flow velocity were measured in
the supine position at rest and after release of 1, 3 and 5 min
of transient arterial occlusion before and 1 h after oral
ingestion of study drug (to correspond to peak plasma
concentration after oral dosing [17]) by an investigator
blinded to treatment assignment. Seated blood pressure was
determined in triplicate before and 1 h after the study drug
with the cuff method. Mean arterial pressure was calculated
from a standard formula. Heart rate and rhythm were
electrocardiographically monitored throughout the study.
Data analysis. Values are expressed as mean 6 SEM. The
primary end point of the study was a change in flow-
mediated vasodilation from pretreatment values after oral
administration of sildenafil when compared with placebo.
Secondary end points were mean blood flow velocity and
tolerability/safety parameters (heart rate, blood pressure,
and reported adverse events). Differences in flow mediated
dilation before and after study drug were analyzed with a
repeated measures analysis of variance model with two
within group factors (arterial occlusion time, before/after
study drug) and one between group factor (treatment
assignment). Dunnett’s test was used for post-hoc compar-
ison of treatment groups receiving the three doses of
sildenafil versus placebo. A two-tailed p value ,0.05 was
considered statistically significant.
RESULTS
Clinical characteristics. The clinical characteristics of the
four treatment groups (sildenafil 12.5, 25, 50 mg and
placebo) are presented in Table 1. No significant differences
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were present among the treatment groups. Two patients
(one assigned to placebo and one assigned to sildenafil
25 mg) were excluded from the final analysis due to
suboptimal ultrasound images of the brachial artery.
Flow-mediated dilation. Brachial artery diameter at rest
did not differ among the four treatment groups (0.36 6
0.02 cm placebo, 0.41 6 0.01 cm sildenafil 12.5 mg, 0.41 6
0.02 cm sildenafil 25 mg, 0.40 6 0.02 cm sildenafil 50 mg)
before study drug administration and did not significantly
change after study drug administration. Before study drug
administration, flow-mediated dilation after release of 1 and
5 min of arterial occlusion did not significantly differ among
the four treatment groups, whereas by chance, the pretreat-
ment flow-mediated vasodilation after 3 min of arterial
occlusion was lower in the patients assigned to receive
50 mg sildenafil when compared with those assigned to
receive 12.5 mg sildenafil or placebo (p , 0.05, Table 2).
Pretreatment flow-mediated vasodilation was not signifi-
cantly correlated with treatment response (r 5 0.24, p 5
NS). After study drug administration, the change in flow-
mediated dilation from pretreatment values significantly
increased in patients receiving sildenafil 25 mg and patients
receiving sildenafil 50 mg (both p , 0.05) but not in
patients receiving sildenafil 12.5 mg when compared with
patients receiving placebo (Fig. 1, Table 2).
Mean blood flow velocity. Mean brachial artery blood
flow velocity did not differ among the four treatment groups
at rest (7.8 6 0.6 cm/s placebo, 5.5 6 0.5 cm/s sildenafil
12.5 mg, 7.2 6 1.0 cm/s sildenafil 25 mg, 7.5 6 0.5 cm/s
sildenafil 50 mg) before study drug administration and did
not significantly change after study drug administration.
Before study drug administration, mean brachial artery
blood flow velocity after release of 1, 3 and 5 min of arterial
occlusion did not differ among the treatment groups (Table
3). After study drug administration, mean brachial artery
blood flow velocity did not differ among the treatment
groups (Table 3).
Tolerability. Mean arterial pressure did not differ among
the four treatment groups before or after study drug admin-
istration (Table 4). Heart rate was significantly lower in
patients assigned to placebo when compared with the other
treatment groups before and after study drug administration
(Table 4). This finding may be related to a nonsignificant
trend towards increased frequency of use of beta-adrenergic
receptor antagonists as background therapy in patients
assigned to placebo. Pretreatment heart rate did not signif-
Table 1. Clinical Characteristics of Study Population According to Treatment Assignment
Placebo
(n 5 12)
Sildenafil 12.5 mg
(n 5 12)
Sildenafil 25 mg
(n 5 12)
Sildenafil 50 mg
(n 5 12)
Age (yrs) 56 6 3 55 6 3 54 6 3 56 6 3
Gender (n) 8M/4F 10M/2F 11M/1F 10M/2F
NYHA class (n)
Class II 9 7 6 7
Class III 3 5 6 5
Etiology (n)
Ischemic 4 7 9 7
Nonischemic 8 5 3 5
LVEF (%) 28 6 2 23 6 2 24 6 2 27 6 2
Medications (n)
Diuretics 12 12 12 12
ACE inhibitors 12 12 12 12
Digoxin 12 12 10 12
Beta–blocker 10 7 7 8
Co-morbid cond. (n)
Diabetes mellitus 4 2 2 2
h/o HTN 2 6 4 2
Hyperlipidemia 1 5 3 3
h/o tobacco use 8 8 5 8
ACE 5 angiotensin–converting enzyme; cond. 5 condition; F 5 female; h/o 5 history of; HTN 5 hypertension; LVEF 5
left ventricular ejection fraction; M 5 male; NYHA 5 New York Heart Association.
Table 2. Flow-Mediated Vasodilation (Percent Change in Brachial Artery Diameter) After
Release of 1, 3 and 5 Min of Transient Arterial Occlusion Before and After Study Drug
Administration in Patients With Heart Failure According to Treatment Assignment
Before Study Drug After Study Drug
1 min 3 min 5 min 1 min 3 min 5 min
Placebo 1.4 6 0.9 2.1 6 1.0 3.4 6 1.0 2.1 6 0.8 2.3 6 0.9 4.0 6 0.8
Sildenafil 12.5 mg 1.4 6 0.9 2.8 6 0.8 3.6 6 0.7 3.1 6 0.8 5.1 6 1.3 5.0 6 0.9
Sildenafil 25 mg 0.02 6 0.7 0.7 6 0.7 1.5 6 1.1 3.3 6 1.6 4.5 6 1.9 5.5 6 1.8
Sildenafil 50 mg 20.4 6 0.4 20.2 6 0.5* 1.0 6 0.7 3.3 6 1.3 3.9 6 1.1 4.8 6 1.5
*indicates p , 0.05 vs. sildenafil 12.5 mg and placebo.
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icantly correlate with treatment response (r 5 0.20, p 5
NS). In a post-hoc analysis, flow-mediated vasodilation
after release of 1, 3 or 5 min of arterial occlusion did not
differ in patients with or without background beta-
adrenergic receptor antagonist therapy. The study drug was
generally well-tolerated. Reported side effects were flushing
in seven patients (three treated with sildenafil 12.5mg, three
treated with sildenafil 25 mg and one patient treated with
sildenafil 50 mg) and mild headache and lightheadedness in
one patient treated with placebo.
Normal controls. Resting brachial artery diameter (0.40 6
0.02 cm) in normal subjects did not differ from that of
patients with heart failure. Resting brachial artery mean
blood flow velocity (8.6 6 0.6 cm/s) was significantly
greater in normal subjects when compared with that of
patients with heart failure (p , 0.05). Flow-mediated
vasodilation after release of 1, 3 and 5 min of transient
arterial occlusion (2.8 6 0.8, 4.2 6 0.7 and 6.1 6 1.0%,
respectively) and mean brachial artery blood flow velocity
after release of 1, 3 and 5 min of transient arterial occlusion
(30.4 6 2.4, 52.6 6 5.0 and 58.4 6 6.6 cm/s, respectively)
were significantly greater in normal subjects when compared
with that of patients with heart failure (both p , 0.05).
DISCUSSION
The present data demonstrate a significant increase in
flow-mediated dilation in the brachial artery after adminis-
tration of sildenafil 25 and 50 mg when compared with
placebo in ambulatory patients with chronic heart failure.
These findings suggest that type 5 phosphodiesterase inhi-
bition with sildenafil acutely improves endothelium-
dependent vasodilation in patients with chronic heart fail-
ure.
Sildenafil mechanism of action. Sildenafil is a specific
inhibitor of type 5 phosphodiesterase, the predominant
isozyme for cGMP degradation in smooth muscle, includ-
ing human vascular smooth muscle (18). The clinical
benefits of sildenafil in erectile dysfunction are mediated by
enhanced cGMP-dependent effects related to nitric oxide
signaling in corpus cavernosum (11,19,20). Flow-mediated
dilation is partly mediated by activation of soluble guanylate
cyclase in vascular smooth muscle in response to shear
stress-induced endothelial release of nitric oxide (2). Zap-
rinast, a type 5 phosphodiesterase inhibitor not available for
clinical use, enhances endothelium-dependent, nitric oxide-
mediated vasodilation in isolated rat aortic rings, in the
intact lamb and cat pulmonary circulation with experimental
Figure 1. Change (means 6 SEM) in flow-mediated dilation (FMD, %) from pretreatment values after release of 1, 3 and 5 min of arterial occlusion in
patients treated with placebo (closed squares), sildenafil 12.5 mg (open squares), sildenafil 25 mg (open circles) and sildenafil 50 mg (open triangles).
Table 3. Mean Brachial Artery Blood Flow Velocity (cm/s) After Release of 1, 3 and 5 Min of
Transient Arterial Occlusion Before and After Study Drug Administration in Patients With
Heart Failure According to Treatment Assignment
Before Study Drug After Study Drug
1 min 3 min 5 min 1 min 3 min 5 min
Placebo 26.7 6 3.8 42.1 6 5.0 49.5 6 4.4 33.5 6 2.5 49.4 6 4.4 55.4 6 4.5
Sildenafil 12.5 mg 25.3 6 3.0 39.3 6 4.7 45.1 6 6.3 25.7 6 2.9 45.1 6 6.3 48.3 6 6.6
Sildenafil 25 mg 30.6 6 4.3 43.7 6 5.6 47.7 6 7.0 27.8 6 4.7 41.8 6 8.6 47.2 6 7.4
Sildenafil 50 mg 28.8 6 2.1 46.8 6 5.6 55.6 6 5.7 27.7 6 2.7 46.2 6 4.2 48.3 6 4.4
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pulmonary hypertension and in the cat hindlimb circulation
(21–24). Increased flow-mediated vasodilation in this study
is likely due to a direct effect of sildenafil on the brachial
artery since the stimulus for flow-mediated dilation, mean
blood flow velocity (the predominant physiological deter-
minant of shear stress), did not differ among treatment
groups before and after study drug administration. Absence
of a change in mean blood flow velocity after sildenafil
indicates a primary effect on conduit vessel function (6). The
drug-induced increase in flow-mediated vasodilation was
observed in response to submaximal (1 and 3 min occlu-
sions) and maximal (5 min occlusion) vasodilatory stimuli.
The absence of a ceiling effect in response to a maximal
stimulus is in accord with recent studies, which demon-
strated improvement in flow-mediated vasodilation in re-
sponse to 5 min of arterial occlusion after acute administra-
tion of ascorbic acid and quinaprilat (25,26).
Mechanisms of endothelial dysfunction in heart failure.
Endothelium-dependent vasodilation in response to hor-
monal agonists and shear stress is decreased in the skeletal
muscle circulation of patients with chronic heart failure
when compared with that of normal subjects (3,4,6). The
current finding of decreased flow-mediated vasodilation
when compared with normal subjects before administration
of the study drug is concordant with these past studies.
Decreased flow-mediated dilation in patients with heart
failure can be attributed to decreased shear stress signal
(since mean blood flow velocity was decreased when com-
pared with normal subjects) and reduced activity of the
L-arginine-nitric oxide metabolic pathway (27). In addi-
tion, impaired vasodilation in response to endothelium-
derived nitric oxide in patients with heart failure is partly
attributable to hyporesponsiveness of vasorelaxation effector
mechanisms in vascular smooth muscle. Previous studies of
the vasodilatory responses to intraarterial administration of
activators of soluble guanylate cyclase, nitroglycerin and
nitroprusside in patients with heart failure have yielded
conflicting findings. While some investigators have reported
normal vasodilatory responses (3,28), the majority have
demonstrated that the vasodilatory responses to nitrosova-
sodilators are significantly decreased in patients with heart
failure when compared with normal subjects (5–7,29–32).
The vasodilatory responses to intraarterial administration of
atrial natriuretic peptide and brain natriuretic peptide,
which mediate vasodilation through activation of particulate
guanylate cyclase in vascular smooth muscle, are also atten-
uated in patients with heart failure when compared with
normal subjects (8). In contrast, the vasodilation responses
to intraarterial administration of the cyclic adenosine mono-
phosphate dependent vasodilators, isoproterenol and phen-
tolamine, did not differ in patients with congestive heart
failure when compared with normal subjects (28,29). Taken
together, these observations suggest a specific defect in
cGMP-mediated vasodilation is present in the vascular
smooth muscle of patients with congestive heart failure.
Role of type 5 phosphodiesterase. Impaired cGMP-
mediated vasodilation in heart failure may be due to
decreased synthesis of cGMP (via both soluble and partic-
ulate guanylate cyclase pathways), increased degradation of
cGMP by phosphodiesterase or downstream abnormalities
in the cGMP signal transduction pathway (9). In isolated
glomeruli from dogs with heart failure induced by rapid
ventricular pacing, cGMP accumulation in response to atrial
natriuretic peptide and sodium nitroprusside is decreased
when compared with normal controls and is associated with
increased phosphodiesterase hydrolyzing activity of cGMP
(33). Neurohormonal activation in heart failure may con-
tribute to alterations in cGMP metabolism since, in cultured
rat mesangial cells, angiotensin II attenuates the effects of
atrial natriuretic peptide on cGMP accumulation, in part, by
increasing phosphodiesterase hydrolyzing activity (34).
Study limitations. Interpretation of the current findings is
limited by the short duration of therapy and the relatively
small number of patients in each treatment group. Small
group differences in pretreatment values of flow-mediated
vasodilation and heart rate are unlikely to explain our
findings because neither of these variables correlated with
treatment response. All patients in the study had compen-
sated chronic heart failure and were receiving therapy
consisting of several different classes of medications. Al-
though medications were discontinued before the measure-
ments, an effect of medications on the current findings
cannot be excluded. Consistent with the findings of recent
large survival trials (35,36), co-morbid conditions, which
may influence endothelium-dependent, flow-mediated di-
lation, were present in this study population. Background
medication use and prevalence of co-morbid conditions are
unlikely to account for the current findings since baseline
clinical characteristics did not differ among the four treat-
ment groups. Since normal subjects did not receive sildenafil
Table 4. Heart Rate and MAP Before and After Study Drug Administration in Patients With
Heart Failure According to Treatment Assignment
HR
Before
(min21)
HR After
(min21)
MAP Before
(mm Hg)
MAP After
(mm Hg)
Placebo 64 6 3* 64 6 3* 91.7 6 2.0 90.1 6 2.8
Sildenafil 12.5 mg 74 6 4 71 6 5 90.8 6 4.7 86.3 6 4.9
Sildenafil 25 mg 74 6 3 75 6 3 85.4 6 2.7 82.4 6 2.9
Sildenafil 50 mg 77 6 6 76 6 6 88.3 6 4.3 85.7 6 5.0
*indicates p , 0.05 vs. other treatment groups.
HR 5 Heart rate; MAP 5 mean arterial pressure.
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in this study, our findings cannot determine whether im-
proved flow-mediated vasodilation after sildenafil was a
nonspecific effect or related to reversal of a pathophysiolog-
ical mechanism present in heart failure.
Conclusions. This study demonstrated that a single oral
dose of sildenafil 25 and 50 mg acutely increases flow-
mediated endothelium-dependent vasodilation in the bra-
chial artery of patients with chronic heart failure when
compared with placebo. Due to the small number of
patients per treatment group, these findings require confir-
mation in larger studies. Sildenafil was well-tolerated in the
study population without significant changes in heart rate or
blood pressure. The most frequently reported side effect,
flushing, in seven patients (15%) is comparable to the
incidence of flushing reported in controlled clinical trials of
other patient populations (37). Since its introduction into
clinical practice for the treatment of erectile dysfunction,
sildenafil has been rarely associated with adverse cardiovas-
cular events (38). Further studies are warranted to charac-
terize the safety and efficacy of longer term type 5 phospho-
diesterase inhibition in the treatment of endothelial
dysfunction in chronic heart failure.
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